Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes?

International Journal of Cardiology

Volumn 96, Issue 2, 2004, Pages 151-155

  Wolak, Arik ^a   Ayzenberg, Yosef ^a   Cafri, Carlos ^a   Gilutz, Harel ^a   Ilia, Reuben ^a   Zahger, Doron ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Acute coronary syndromes; Coronary intervention; Enoxaparin; Heparin

Indexed keywords

ENOXAPARIN; HEPARIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; CORONARY CARE UNIT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 3342996203     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.05.032     Document Type: Article

References (11)

1. Antman E.M., Cohen M., Radley D., McCabe C., Rush J., Premmereur J., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 100:1999;1602-1608
2. Cohen M., Demers C., Gurfinkel E.P., Turpie A.G.G., Fromell G.J., Goodman S., et al. The efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. New Engl. J. Med. 337:1997;447-452
3. Antman E.M., McCabe C.H., Gurfinkel E.P., Turpie A.G.G., Bernink P.J.L.M., Salein D., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 100:1999;1593-1601
4. Collet J.P., Montalescot G., Lison L., Choussat R., Ankri A., Drobinski G., et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 103:2001;658-663
5. Kereiakes D.J., Montalescot G., Antman E.M., Cohen M., Darius H., Ferguson J.J., et al. Low-molecular-weight heparin therapy for non-ST elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am. Heart J. 144:2002;615-624
6. Fox K., Antman E., Cohen M., Bigonzi F. ESSENCE/TIMI 11B Investigators. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am. J. Cardiol. 90:2002;477
7. Karsch K.R., Preisack M.B., Baildon R., Eschenfelder V., Foley D., Garcia E.J., et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, early administration of reviparin in a double-blind unfractionated heparin and placebo-controlled evaluation. J. Am. Coll. Cardiol. 28:1996;1437-1443
8. Rabah M.M., Premmereur J., Graham M., Fareed J., Hoppensteadt D.A., Grines L.L., et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am. J. Cardiol. 84:1999;1391-1395
9. Young J.J., Kereiakes D.J., Grines C.L. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J. Invasive Cardiol. 12:(Suppl. E):2000;E14-E18. (discussion E25-8)
10. Kereiakes D.J., Fry E., Matthai W., Niederman A., Barr L., Brodie B., et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first" J. Invasive Cardiol. 12:(Suppl. A):2000 (February);1A-5A
11. Blazing M, for the Aggrastat to Zocor Investigators. Aggrastat to Zocor (A to Z, Phase A) Presented at Late Breaking Clinical Trials, 52nd Scientific Sessions of the American College of Cardiology, Chicago, IL; 2003 (March).